BIOMAT Database Logo BIOMAT Database Logo

Cardiovascular Implications of Metabolic Dysfunction-Associated Fatty Liver Disease. 2023

Zhewen Ren, and Anke Wesselius, and Coen D A Stehouwer, and Martijn C G J Brouwers
Division of Endocrinology and Metabolic Disease, Department of Internal Medicine, Maastricht University Medical Center, P Debyelaan 25, 6229 HX Maastricht, the Netherlands; CARIM School for Cardiovascular Diseases, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands; Laboratory for Metabolism and Vascular Medicine, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands.

Both nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated fatty liver disease (MAFLD) have been associated with incident cardiovascular disease (CVD), independent of confounders. Causality has recently been inferred by Mendelian randomization studies. Although these findings have contributed to current guidelines that recommend screening for and treatment of cardiovascular risk factors, it not yet clear how to position NAFLD/MAFLD in cardiovascular risk estimation scores and, consequently, which treatment targets should be used. This review aims to provide practical tools as well as suggestions for further research in order to effectively prevent CVD events in patients with NAFLD/MAFLD.

UI MeSH Term Description Entries
D008659 Metabolic Diseases Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed) Thesaurismosis,Diseases, Metabolic,Disease, Metabolic,Metabolic Disease,Thesaurismoses
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D002319 Cardiovascular System The HEART and the BLOOD VESSELS by which BLOOD is pumped and circulated through the body. Circulatory System,Cardiovascular Systems,Circulatory Systems
D065626 Non-alcoholic Fatty Liver Disease Fatty liver finding without excessive ALCOHOL CONSUMPTION. Fatty Liver, Nonalcoholic,NAFLD,Nonalcoholic Fatty Liver Disease,Nonalcoholic Steatohepatitis,Fatty Livers, Nonalcoholic,Liver, Nonalcoholic Fatty,Livers, Nonalcoholic Fatty,Non alcoholic Fatty Liver Disease,Nonalcoholic Fatty Liver,Nonalcoholic Fatty Livers,Nonalcoholic Steatohepatitides,Steatohepatitides, Nonalcoholic,Steatohepatitis, Nonalcoholic

Related Publications

Zhewen Ren, and Anke Wesselius, and Coen D A Stehouwer, and Martijn C G J Brouwers
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention.
December 2022, Cardiovascular diabetology,
Zhewen Ren, and Anke Wesselius, and Coen D A Stehouwer, and Martijn C G J Brouwers
Metabolic Dysfunction-Associated Fatty Liver Disease Better Predicts Incident Cardiovascular Disease.
July 2022, Gut and liver,
Zhewen Ren, and Anke Wesselius, and Coen D A Stehouwer, and Martijn C G J Brouwers
Metabolic Dysfunction-Associated Fatty Liver Disease, Statins, and Atherosclerotic Cardiovascular Disease.
January 2024, The American journal of medicine,
Zhewen Ren, and Anke Wesselius, and Coen D A Stehouwer, and Martijn C G J Brouwers
Implications of metabolic dysfunction associated fatty liver disease in COVID-19.
February 2023, World journal of clinical cases,
Zhewen Ren, and Anke Wesselius, and Coen D A Stehouwer, and Martijn C G J Brouwers
Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis.
January 2022, Frontiers in endocrinology,
Zhewen Ren, and Anke Wesselius, and Coen D A Stehouwer, and Martijn C G J Brouwers
Atherosclerotic cardiovascular disease risk difference in metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease.
November 2021, Hepatology research : the official journal of the Japan Society of Hepatology,
Zhewen Ren, and Anke Wesselius, and Coen D A Stehouwer, and Martijn C G J Brouwers
Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
May 2022, Gut and liver,
Zhewen Ren, and Anke Wesselius, and Coen D A Stehouwer, and Martijn C G J Brouwers
Metabolic dysfunction-associated fatty liver disease: advances in genetic and epigenetic implications.
April 2022, Current opinion in lipidology,
Zhewen Ren, and Anke Wesselius, and Coen D A Stehouwer, and Martijn C G J Brouwers
Cardiovascular disease in metabolic-associated fatty liver disease.
April 2023, Current opinion in endocrinology, diabetes, and obesity,
Zhewen Ren, and Anke Wesselius, and Coen D A Stehouwer, and Martijn C G J Brouwers
Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
March 2023, Liver international : official journal of the International Association for the Study of the Liver,
Copied contents to your clipboard!